These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis. Neilan AM, Landovitz RJ, Le MH, Grinsztejn B, Freedberg KA, McCauley M, Wattananimitgul N, Cohen MS, Ciaranello AL, Clement ME, Reddy KP, Hyle EP, Paltiel AD, Walensky RP. Ann Intern Med; 2022 Apr 05; 175(4):479-489. PubMed ID: 35099992 [Abstract] [Full Text] [Related]
5. Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation. Cambiano V, Miners A, Dunn D, McCormack S, Ong KJ, Gill ON, Nardone A, Desai M, Field N, Hart G, Delpech V, Cairns G, Rodger A, Phillips AN. Lancet Infect Dis; 2018 Jan 05; 18(1):85-94. PubMed ID: 29054789 [Abstract] [Full Text] [Related]
6. Optimising HIV pre-exposure prophylaxis and testing strategies in men who have sex with men in Australia, Thailand, and China: a modelling study and cost-effectiveness analysis. Zhao R, Fairley CK, Cook AR, Phanuphak N, He S, Tieosapjaroen W, Chow EPF, Phillips TR, Jin Tan RK, Wei Y, Shen M, Zhuang G, Ong JJ, Zhang L. Lancet Glob Health; 2024 Feb 05; 12(2):e243-e256. PubMed ID: 38245115 [Abstract] [Full Text] [Related]
7. A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men. Drabo EF, Hay JW, Vardavas R, Wagner ZR, Sood N. Clin Infect Dis; 2016 Dec 01; 63(11):1495-1504. PubMed ID: 27558571 [Abstract] [Full Text] [Related]
13. Cost-effectiveness analysis of HIV pre-exposure prophylaxis in Japan. Mizushima D, Nagai Y, Mezzio D, Harada K, Piao Y, Barnieh L, El Moustaid F, Cawson M, Taniguchi T. J Med Econ; 2023 Dec 01; 26(1):886-893. PubMed ID: 37421417 [Abstract] [Full Text] [Related]
14. Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States. Brogan AJ, Davis AE, Mellott CE, Fraysse J, Metzner AA, Oglesby AK. Pharmacoeconomics; 2024 Apr 01; 42(4):447-461. PubMed ID: 38267806 [Abstract] [Full Text] [Related]
17. Economic evaluation of HIV pre-exposure prophylaxis among men-who-have-sex-with-men in England in 2016. Ong KJ, Desai S, Field N, Desai M, Nardone A, van Hoek AJ, Gill ON. Euro Surveill; 2017 Oct 01; 22(42):. PubMed ID: 29067902 [Abstract] [Full Text] [Related]
19. Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058. van de Vijver DAMC, Richter AK, Boucher CAB, Gunsenheimer-Bartmeyer B, Kollan C, Nichols BE, Spinner CD, Wasem J, Schewe K, Neumann A. Euro Surveill; 2019 Feb 01; 24(7):. PubMed ID: 30782266 [Abstract] [Full Text] [Related]